Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider Premier Biotech (“Premier” or the “Company”) has acquired National Test Systems (“NTS”), a leading provider of rapid point-of-care diagnostic drug screening supplies and services throughout the United States.

NTS serves over 1,500 facilities throughout the United States, primarily in Government and Behavioral Health end markets through a consultative, knowledge-first approach. The addition of NTS enhances Premier’s customer base and strengthens the Company’s leadership within the Government and Behavioral Health channel. NTS CEO, Andrew Panico, will remain involved with the Company to support continued growth and a successful transition.

“We are excited about the partnership opportunity to bring Premier’s full suite of products and services to our growing customer base. Specifically, Premier’s offering in oral fluid testing with its OralTox® device and complete laboratory solutions provides new ways for us to support our customers,” said Panico.

“The acquisition marks a pivotal step in our growth journey and bolsters our leadership position across the drug and alcohol testing industry,” said Premier CEO Matt Michalik. “NTS adds meaningful client depth to our Government and Behavioral Health businesses, complementary point-of-care testing solutions with cross sell potential and a fantastic team to our growing organization. We are thrilled for this partnership.”

Premier Biotech has completed four acquisitions since partnering with ACP in November of 2022. The Company will continue to pursue additional acquisitions and collaboration opportunities to further accelerate its growth. ACP Managing Partner Rob Langley, Operating Partner Ervin Cash, Principal Matt Bowen and Senior Associate Sarah Mahosky worked alongside Premier Management on the transaction.

About Premier Biotech

Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The Company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions designed to simplify and provide a seamless end-to-end experience for customers. Premier differentiates itself through its fully integrated service offering that is augmented with high levels of service, technical expertise and configurability. The Company’s integrated offering is utilized in workplace (pre-employment and post-employment), government (child and family services, probation, parole, corrections, law enforcement and DOT) and healthcare settings. For more information, visit innovation.premierbiotech.com.

About Align Capital Partners

Align Capital Partners is a growth-oriented private equity firm that partners with business owners and management teams to help create shared success. ACP manages $1.8 billion in committed capital with investment teams in Cleveland and Dallas. ACP brings experience and resources to help lower-middle market companies accelerate their growth, to the benefit of management, employees, and the firm’s investors. ACP makes control investments in differentiated companies within the business services, technology, specialty manufacturing and distribution sectors. For more information, visit aligncp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105086375/en/

The acquisition marks a pivotal step in Premier's growth journey and bolsters the Company's leadership position across the drug and alcohol testing industry.